HCC therapies - Lessons learned

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 7, 2014, Pages 447-452

  Wörns, Marcus Alexander ^a   Galle, Peter Robert ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; LINIFANIB; OXALIPLATIN; SORAFENIB; SUNITINIB; TIVANTINIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE;

CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903816764     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.10     Document Type: Review

References (49)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Worns, M. A., Weinmann, A., Schuchmann, M. & Galle, P. R. Systemic therapies in hepatocellular carcinoma. Dig. Dis. 27, 175-188 (2009).
3. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
4. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
5. Bruix, J. & Sherman, M. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022 (2011).
6. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
7. Worns, M. A. & Galle, P. R. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin. Investig. Drugs 19, 615-629 (2010).
8. Llovet, J. M. et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008).
9. Worns, M. A. Systemic therapy and synergies by combination. Dig. Dis. 31, 104-111 (2013).
10. Cheng, A. L. et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067-4075 (2013).
11. Cainap, C. et al. Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. J. Clin. Oncol. 30 (Suppl. 34), 249 (2013).
12. Johnson, P. J. et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524 (2013).
13. Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010).
14. Zhu, A. X. et al. SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma (HCC) [abstract]. Eur. J. Cancer 48 (Suppl.) 2 (2012).
15. Qin, S. et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501-3508 (2013).
16. Llovet, J. M. et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516 (2013).
17. Novartis study of Afinitor® in advanced liver cancer does not meet primary endpoint of overall survival. Novartis [online], http://www.novartis. com/newsroom/media-releases/en/2013/1721562.shtml (2013).
18. Worns, M. A. & Galle, P. R. Future perspectives in hepatocellular carcinoma. Dig. Liver Dis. 42 (Suppl. 3), S302-S309 (2010).
19. Villanueva, A. & Llovet, J. M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 18, 1824-1826 (2012).
20. Villanueva, A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. J. Hepatol. 59, 392-395 (2013).
21. Kelley, R. K. & Venook, A. P. Novel therapeutics in hepatocellular carcinoma. Am. Soc. Clin. Oncol. Educ. Book 2013, 137-142 (2013).
22. Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329-338 (1999).
23. Forner, A., Llovet, J. M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012).
24. Villanueva, A., Newell, P., Chiang, D. Y., Friedman, S. L. & Llovet, J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007).
25. Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
26. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
27. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
28. Marquardt, J. U. & Andersen, J. B. Next-generation sequencing: application in liver cancer-past, present and future? Biology (Basel) 1, 383-394 (2012).
29. Schirmacher, P. et al. Fighting the bushfire in HCC trials. J. Hepatol. 55, 276-277 (2011).
30. Villanueva, A. & Llovet, J. M. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. Hepatology 56, 2416-2419 (2012).
31. Pantel, K. & Alix-Panabieres, C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 73, 6384-6388 (2013).
32. Santoro, A. et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55-63 (2013).
33. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01755767?term=metiv&rank=1 (2013).
34. Schmieder, R. et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161-1171 (2013).
35. Zhu, A. X. et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 19, 920-928 (2013).
36. Catalogue of Somatic Mutations in Cancer [online], http://cancer.sanger. ac.uk/cancergenome/projects/cosmic/.
37. Assenat, E. et al. Sorafenib alone versus sorafenib combined with gemcitabine and oxaliplatin (GEMOX) in the first-line treatment of advanced hepatocellular carcinoma: final results of the randomized phase II GoNext trial (a UNICANCER/FFCD/PRODIGE 10 study) [abstract]. Eur. J. Cancer 49 (Suppl. 2), 2467 (2013).
38. US National Library of Medicine ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01015833?term=CALGB-80802&rank=1 (2013).
39. Llovet, J. M., Burroughs, A. & Bruix, J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003). (Pubitemid 37518510)
40. ArQule Announces Third Quarter Fiscal 2013 Results. Arqule [online], http://investors.arqule.com/releasedetail.cfm?releaseid=805238 (2013).
41. Reig, M. et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second line trial design. Hepatology 58, 2023-2031 (2013).
42. Kelley, R. K. Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials. J. Clin. Oncol. 31, 3483-3486 (2013).
43. Shao, Y. Y. et al. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy. J. Hepatol. 60, 313-318 (2014).
44. He, A. R. & Goldenberg, A. S. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap. Adv. Gastroenterol. 6, 447-458 (2013).
45. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01761266?term= lenvatinib+AND+sorafenib&rank=1 (2013).
46. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01140347?term=REACH+ramucirumab&rank= 1 (2013).
47. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01287585?term=POLARIS2009-2001&rank=1 (2013).
48. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01774344?term=regorafenib+hcc&rank=2 (2014).
49. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01908426?term=celestial+cabozantinib& rank=1 (2014).